Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Single-center Pilot Study to Investigate Alglucosidase Alfa (20 mg/kg) Frequency Reduction From 2 to 4 Weeks in a Subgroup of Elderly Patients With Late-onset Pompe Disease (TRIPOD-Study)

NCT06575829 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT06575829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06575829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Single-center Pilot Study to Investigate Alglucosidase Alfa (20 mg/kg) Frequency Reduction From 2 to 4 Weeks in a Subgroup of Elderly Patients With Late-onset Pompe Disease (TRIPOD-Study)
Lead sponsor
Erasmus Medical Center
Phase
Phase 4
Overall status
Not yet recruiting
Start date
October 1, 2024
Completion date
December 31, 2027
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acid maltase deficiency, gaa deficiency, glycogen storage disease type ii, pompe disease (late-onset)